587 related articles for article (PubMed ID: 30449681)
1. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio MA; Reibe S; Shalapour S; Ooi GJ; Watt MJ; Karin M
Cell Metab; 2019 Jan; 29(1):18-26. PubMed ID: 30449681
[TBL] [Abstract][Full Text] [Related]
2. Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma.
Green CD; Spiegel S
Adv Biol Regul; 2023 Jan; 87():100925. PubMed ID: 36706611
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
5. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
6. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P
Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522
[TBL] [Abstract][Full Text] [Related]
7. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
[TBL] [Abstract][Full Text] [Related]
11. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
Jühling F; Hamdane N; Crouchet E; Li S; El Saghire H; Mukherji A; Fujiwara N; Oudot MA; Thumann C; Saviano A; Roca Suarez AA; Goto K; Masia R; Sojoodi M; Arora G; Aikata H; Ono A; Tabrizian P; Schwartz M; Polyak SJ; Davidson I; Schmidl C; Bock C; Schuster C; Chayama K; Pessaux P; Tanabe KK; Hoshida Y; Zeisel MB; Duong FH; Fuchs BC; Baumert TF
Gut; 2021 Jan; 70(1):157-169. PubMed ID: 32217639
[TBL] [Abstract][Full Text] [Related]
12. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
[TBL] [Abstract][Full Text] [Related]
13. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
14. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
15. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
16. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
17. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
Boslem E; Reibe S; Carlessi R; Smeuninx B; Tegegne S; Egan CL; McLennan E; Terry LV; Nobis M; Mu A; Nowell C; Horadagoda N; Henstridge DC; Mellett NA; Timpson P; Jones M; Denisenko E; Forrest ARR; Tirnitz-Parker JEE; Meikle PJ; Rose-John S; Karin M; Febbraio MA
Sci Adv; 2023 Sep; 9(37):eadh0831. PubMed ID: 37703359
[TBL] [Abstract][Full Text] [Related]
19. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
[TBL] [Abstract][Full Text] [Related]
20. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
